

Edgar Filing: CYTOGEN CORP - Form 8-K

CYTOGEN CORP
Form 8-K
July 03, 2003

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): June 18, 2003

CYTOGEN CORPORATION

(Exact Name of Registrant as Specified in Charter)

| | | |
|---|--------------------------|--------------------------------------|
| Delaware | 000-14879 | 222322400 |
| ----- | ----- | ----- |
| (State or Other Jurisdiction of Incorporation) | (Commission File Number) | (IRS Employer Identification No.) |
| 650 College Road East, Suite 3100, Princeton, NJ | | 08540 |
| ----- | ----- | ----- |
| (Address of Principal Executive Offices) | | (Zip Code) |

(609) 750-8200

(Registrant's telephone number,
including area code)

(Former Name or Former Address, if Changed Since Last Report)

Item 5. Other Events and Required FD Disclosure.

On June 18, 2003, Advanced Magnetix, Inc. ("Advanced Magnetix") and Cytogen Corporation ("Cytogen") announced in a press release the publication of clinical data in the New England Journal of Medicine showing that magnetic resonance imaging with Combidex(R), Advanced Magnetix's investigational iron oxide nanoparticle used to aid in the diagnosis of lymph node disease, allows for the noninvasive assessment of lymph nodes in patients with prostate cancer. Cytogen has a license with Advanced Magnetix for exclusive marketing rights to

Edgar Filing: CYTOGEN CORP - Form 8-K

Combidex(R) in the United States.

Such press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. The foregoing description of such press release is qualified in its entirety by reference to such document.

Item 7. Financial Statements, Pro Forma Financial Information and Exhibits.

(c) Exhibits.

| Exhibit No. ----- | Description ----- |
|----------------------|-----------------------------------|
| 99.1 | Press release dated June 18, 2003 |

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Cytogen Corporation

By: /s/ Michael D. Becker

Michael D. Becker,
President and Chief Executive Officer

Date: July 3, 2003